Use of IL-18 inhibitors for treatment or prevention of sepsis

An inhibitor, a sepsis technology, applied in the application field of IL-18 inhibitor in the treatment or prevention of sepsis, which can solve the problems of reducing inflammation and blocking the maturation of IL-1β

Inactive Publication Date: 2004-09-15
YEDA RES & DEV CO LTD
View PDF12 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

On the other hand, it induces the production of nitric oxide (NO), a caspase-1 inhi...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of IL-18 inhibitors for treatment or prevention of sepsis
  • Use of IL-18 inhibitors for treatment or prevention of sepsis
  • Use of IL-18 inhibitors for treatment or prevention of sepsis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0166] Example 1 Serum IL-18BPa and IL-18 levels of healthy individuals and patients with sepsis

[0167] Measuring specific circulating cytokines and their natural inhibitors in healthy individuals and patients can yield information about their involvement in disease progression and severity. As mentioned in the Background section, a key regulator of sepsis is IFN-γ. Because IL-18 is a co-inducer of IFN-γ, the levels of IL-18 and its natural inhibitor, IL-18BP splice variant a, were monitored in patients with sepsis and compared with healthy subjects using a specific ELISA assay. The levels found were compared (Example 3).

[0168] IL-18 and IL-18BPa levels in healthy subjects

[0169] The mean IL-18 level in 107 healthy subjects was 64±17 pg / ml measured by electrochemiluminescence (ECL, Pomerantz et al., 2001). The degree of interference of related proteins was tested by ECL method. It was found that it was not affected in any way in the presence of mature IL-1β or proIL-1...

Embodiment 2

[0179] Example 2 IL-18BPa induces production of Staphylococcus epidermidis in cells contained in whole blood samples of healthy subjects

[0180] Effect of IFN-γ

[0181] As mentioned in the Background section, the Gram-positive bacterium Staphylococcus epidermidis is known to cause sepsis. The main cause of this disease is the induction of cytokines such as IL-1, IFN-γ and TNF-α. Since IL-18 is a co-inducer of IFN-γ, the effect of IL-18 inhibition on the induction of IFN-γ production by S. epidermidis was tested. IL-18BPa was used as an inhibitor of IL-18, a histidine-tagged recombinant form produced in Chinese hamster ovary cells.

[0182] Take 0.5 ml of blood and 0.5 ml of RPMI growth medium containing Staphylococcus epidermidis (from ATCC) with IL-18BP or only Staphylococcus epidermidis (Cellgro Mediatech, Hendon.VA, supplemented with 10 mM L-glutamine, 100 U / ml penicillin , 100 μg / ml streptomycin and 10% FBS [Gibco BRL, Grand Island, NY]) were mixed in a 5 ml ...

Embodiment 3

[0186] Example 3 Establishment of IL-18BP-specific ELISA test

[0187] The ELISA assay compared two anti-IL-18BPa antibodies: mouse monoclonal antibody 582.10, which is a subclone of monoclonal antibody 582 described in Example 4, used as a capture antibody, and a rabbit polyclonal antibody for detection (implemented Example 4). ELISA well plates (Maxisorb; Nunc A / S, Roskilde, Denmark) with microtiter 96 wells were coated with anti-IL-18BPa mAb 582.10 (subclone of mAb 582, 4 μg / ml in PBS), overnight at 4 °C. Plates were washed with 0.05% Tween 20 in PBS (wash solution) and blocked (2 hours, 37° C.) with a 1:10 dilution of BSA stock solution / water (KPL, Geithesburg, MD). The BSA stock solution was diluted 1:15 (diluent) with water and used to dilute all test samples and detection antibodies. Serum samples were diluted at least 1:5 with diluent and 100 microliter aliquots were added to the wells. Highly purified human IL-18BPa (made in Chinese hamster ovary cells and purifie...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a method of treatment and/or prevention of sepsis and other diseases characteristic to the Systemic Inflammatory Response Syndrone (SIRS), including severe sepsis, septic shock and sepsis related to cardiac dysfunction.

Description

technical field [0001] This application has the benefit of US Provisional Patent Application No. 60 / 291,463, filed May 16, 2001, the disclosure of which is incorporated by reference. [0002] The present invention relates to the application of IL-18 inhibitors in the treatment and / or prevention of sepsis. Background of the invention [0003] In 1989, factors induced by Mycobacterium bovis and challenged with lipopolysaccharide (LPS) were detected in the sera of infected mice. This factor induces interferon-gamma (IFN-gamma) in normal mouse splenocyte cultures in the presence of interleukin-2 (IL-2) (Nakamura et al., 1989). This factor acts not as a direct inducer of IFN-γ but as a co-stimulator with IL-2, anti-CD3 or mitogens. Attempts to further characterize this activity from endotoxin post-treated mouse serum revealed an apparently homogeneous protein with a molecular weight of 50-55 kDa related to the above activity (Nakamura et al., 1993). Since other cytokines can a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K31/7088A61K38/00A61K38/17A61K38/21A61K38/55A61K39/395A61K47/48A61K48/00A61P7/00A61P9/04A61P29/00A61P31/04A61P43/00C07K16/24C07K16/28
CPCC07K16/2866A61K38/215A61K48/00A61K38/20A61K38/212A61K47/48215A61K39/3955C07K16/244A61K38/1793A61K2039/505A61K47/60A61P29/00A61P31/00A61P31/04A61P37/00A61P43/00A61P7/00A61P9/00A61P9/04A61K2300/00A61K38/21
Inventor C·A·迪纳洛G·范土齐金修铉L·雷兹尼科夫M·鲁宾斯坦D·诺维克B·希瓦茨布德
Owner YEDA RES & DEV CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap